TNFRSF17 and plasma cell myeloma: The first successful clinical experience on the combination of BCMA-specific CAR-T cells and lenalidomide was reported in a patient with refractory IgD-λ multiple myeloma, who displayed disease progression despite multiple lines of therapy, including allogeneic stem cell transplantation and treatment with T cells expressing mouse-derived and human-derived BCMA-specific CARs [67].